Search for stocks /

Laxmi Dental Q3 FY26: ₹660 Mn Revenue, EBITDA Slips, Stock Down 54% in 1 Year — Is This a Root Canal or a Smile Makeover?


1. At a Glance – The Dentist That Investors Are Avoiding

Laxmi Dental Ltd is trading at ₹192, down 54.3% in one year and nearly 38.3% in the last three months. Market cap? ₹1,058 crore. Stock P/E? 39.4. Industry P/E? 35.9.

Q3 FY26 revenue stood at ₹66.04 crore, up 7.09% YoY. But PAT? Just ₹1.96 crore, even after reporting an exceptional item of ₹5.78 crore. Operating margin slipped to 10.54% from 15.25% in the previous quarter.

ROE stands at 21.9%, ROCE at 19.2%. Sounds healthy? Wait till you see the quarterly dip.

The company raised ₹698 crore via IPO in January 2025, and yet the stock has already tested ₹180 against a high of ₹510. That’s not volatility. That’s emotional damage.

So what is this — a dental empire building global brands, or a case study in post-IPO reality check?

Let’s drill deeper.


2. Introduction – India’s Dental Disruptor or IPO Hangover?

Laxmi Dental claims to be India’s only end-to-end integrated dental products company. Which basically means: they don’t just fix your tooth, they manufacture the tools, the aligners, the crowns, the pediatric products, and probably the chair you sit on.

Founded in 2004, the company operates across:

  • Dental laboratory services
  • Clear aligners
  • Aligner sheets and machines
  • Pediatric dental products

They serve 22,000+ clinics across 300+ cities and export to 95+ countries. That’s more countries than most Indians have visa stamps for.

Geographical revenue split FY25:

  • India: 67%
  • USA: 20%
  • UK: 8%
  • Others: 6%

It’s not just domestic dentist darling — it’s exporting smiles worldwide.

And then came the IPO. ₹698 crore raised. Fresh issue ₹138 crore for debt repayment, capex, and subsidiary investments.

Now the real question:
Was the IPO a growth accelerator… or just a financial whitening treatment?

Let’s examine.


3. Business Model – WTF Do They Even Do?

Think of Laxmi Dental as the “Tata of Teeth.” They don’t just do one thing.

1) Laboratory Business

Custom crowns, bridges, dentures. High recurring demand. Dentists outsource this work. Laxmi earns per unit.

2) Aligner Solutions

Brands: Illusion Aligners, Bizdent, Taglus.
This is the cool, Instagram-friendly segment. Clear aligners instead of metal braces. Higher margins, scalable, export-friendly.

3) Pediatric Dental Products

Kids-E-Dental brand. Pre-formed crowns for children. Because apparently even milk teeth now need branding.

4) Tech Add-ons

iScanPro intraoral scanners.
Taglus aligner sheets and machines.

They are trying to move from being a “dental lab vendor” to a “branded dental platform.”

And that shift — if executed well — can expand margins.

But Q3 margins say… execution still needs polishing.

So here’s the investor question:
Is this a manufacturing business wearing a brand costume? Or a real brand in the making?


4. Financials Overview – The Numbers Don’t Lie (But They Do Smirk)

Q3 FY26 vs YoY vs QoQ

MetricLatest Qtr (Dec 2025)YoY Qtr (Dec 2024)Prev Qtr (Sep 2025)YoY %QoQ %
Revenue (₹ Cr)66.0461.6772.277.09%-8.61%
EBITDA (₹ Cr)6.969.6211.02-27.7%-36.8%
PAT (₹ Cr)1.964.828.53-59.3%-77.0%
EPS (₹)0.360.931.55-61%-76.7%

Annualised EPS = 0.36 × 4 = ₹1.44

Now calculate P/E ourselves:
CMP ₹192 / ₹1.44 ≈ 133x annualised

Wait.

Reported P/E = 39.4
Annualised Q3 P/E = 133

Which one reflects reality?

The trailing twelve-month EPS is ₹4.22.
That gives 192 / 4.22 ≈ 45.5x.

Market is pricing based on TTM, not current quarter weakness.

But EBITDA and PAT both sharply declined.

So ask yourself:
Is Q3 a blip… or margin compression starting?


5. Valuation Discussion – Fair Value Range Only

Method 1: P/E Based

TTM EPS = ₹4.22
Industry PE = 35.9

Fair Value Range:

  • Lower band: 30 × 4.22 = ₹126
  • Upper band: 40 × 4.22 = ₹168

Method 2: EV/EBITDA

EV = ₹1,058 crore
TTM EBITDA ≈ ₹39 crore
EV/EBITDA ≈ 27x

Industry median ~ 20–22x.

Applying 18–22x:

  • 18 × 39 = ₹702 crore
  • 22 × 39 = ₹858 crore

Per share fair value range implies roughly ₹130–₹165 zone.


Method 3: Simplified DCF

PAT TTM ≈ ₹23 crore
Assume 15% growth for 5 years
Discount rate 12%

Estimated value band: ₹900–₹1,050 crore equity valuation.

Per share range: ₹160–₹185.


Fair Value Range: ₹130 – ₹185

Current Price: ₹192

It’s slightly above our educational fair value band.

Disclaimer:
This fair value range is for educational purposes only and is not investment advice.


6. What’s Cooking – News, Triggers, Drama

Q3 FY26 press release says:

  • Revenue ₹660.4 million
  • Exceptional item ₹57.8 million
  • EBITDA declined

Translation: Core profitability dipped.

Other developments:

  • Acquired 58% stake in AI Dent for ₹2.05 crore
Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!